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Introduction
Neuromyelitis optica (NMO) is a rare, disabling auto-
immune astrocytopathy typically characterized by 
severe and recurrent optic neuritis, longitudinally 
extensive transverse myelitis, and, less commonly, 
brain and brainstem lesions. Incomplete recovery 
from attacks is typical, giving rise to accumulative 
attack-related disability. NMO prevalence is esti-
mated between 0.5 and 4.4/100,000.1,2 To date, no 
controlled clinical studies of NMO have been com-
pleted and no treatment has received regulatory 
approval. Immunosuppressive medications such as 
azathioprine, mycophenolate mofetil, mitoxantrone, 
prednisone, and rituximab are used empirically to pre-
vent attacks,3 although the evidence to support their 
use is limited. Robust clinical trials are required to 
demonstrate the safety and efficacy of potential new 
therapies for NMO.
One area of controversy within the NMO community 
and among regulatory agencies is the appropriateness 
of a placebo-controlled design in this disease.4–8 
Although placebo control can provide unequivocal 
evidence of efficacy, there is legitimate concern about 
not treating patients since untreated subjects may be 
at higher risk of relapses (and their consequences) 
than those receiving empiric active treatments. Some 
investigators have argued that there is sufficient evi-
dence to use empiric therapies as active comparators 
and that superiority to an active, rather than placebo, 
comparator is preferable. However, use of unproven 
active comparators could lead to results that are 
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Background: To date, no treatment for neuromyelitis optica (NMO) has been granted regulatory approval, 
and no controlled clinical studies have been reported.
Objective: To design a placebo-controlled study in NMO that appropriately balances patient safety and 
clinical–scientific integrity.
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receive MEDI-551, a monoclonal antibody that depletes CD19+ B-cells, or placebo. The study design 
has received regulatory, ethical, clinical, and patient approval in over 100 clinical sites in more than 20 
countries worldwide.
Conclusion: The approach we took in the design of the N-MOmentum trial might serve as a roadmap for 
other rare severe diseases when there is no proven therapy and no established clinical development path.
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difficult to interpret.9 For example, if the two active 
therapies appear equivalent, one would not know 
whether they are both effective or both ineffective (or 
even both harmful) as was the case in myasthenia 
gravis study comparing mycophenolate mofetil to 
prednisone.10 If the study drug were found superior, it 
could be as a result of harm caused by the active 
comparator.
N-MOmentum (NCT02200770) is a clinical trial that 
randomizes NMO patients to receive MEDI-551, a 
monoclonal antibody that depletes CD19+ B-cells, or 
a placebo. The key considerations in the design of the 
N-MOmentum study included (1) establishing an eth-
ical framework for conduct of a placebo-controlled 
trial in NMO, (2) assessing the “standard of care” for 
NMO, and (3) implementing study design features 
that provide a scientifically robust study and mitigate 
the risk associated with a placebo-controlled study.
Is there a “standard of care” for NMO?
A fundamental question is whether the immunosup-
pressive medications, currently used for NMO, con-
stitute the “standard of care” and, if so, whether these 
medications need to be used as active controls in clin-
ical trials of new medications. Strictly, to consider an 
intervention to be the standard of care, there should be 
robust scientific data demonstrating the effectiveness 
of the intervention for the treatment of the condition 
in question.
Regulatory agencies and providers may differ in the 
level of evidence required to consider an intervention 
“proven.” Regulatory agencies usually have a higher 
standard than those in clinical practice to make this 
determination. Nonetheless, some scientific criteria 
should be used to assess the available data and to 
determine whether a given treatment meets the stand-
ards of a proven therapy. The American Academy of 
Neurology (AAN) publishes Clinical Practice 
Guidelines for neurological interventions and thera-
pies and categorizes them based on well-defined lev-
els of evidence.11 The AAN rates clinical studies as 
Class I–Class IV based on the scientific rigor of the 
study design. Well-controlled, multi-center, rand-
omized trials are rated Class I. Single-center studies 
that are randomized are rated as Class II. 
Nonrandomized studies or ones in which historical 
controls are used are rated as Class III. Case series, 
case reports, and expert opinions are rated as Class IV. 
The recommendations for clinical practice are based 
on the class of the relevant studies and include four 
grades: “A,” “B,” “C,” and “U.” Level A recommen-
dation requires at least two consistent Class I studies, 
while U is the lowest and is defined as data “inade-
quate” or “conflicting,” meaning that the treatment is 
“unproven.”
To objectively assess the current level of evidence of 
the use of immunosuppressive medications in NMO, 
a systematic literature review was performed using 
accepted methodology.12,13 A level of evidence was 
assigned to each study according to the AAN criteria 
described above. In total, 2438 citations were 
screened, and 105 studies (77 primary studies and 28 
“kins,” defined as multiple publications of the same 
or overlapping series of patients) met inclusion crite-
ria. An additional 116 case reports or case series with 
fewer than four patients were also identified. Of the 
77 primary studies that met the inclusion criteria, 49 
were studies of maintenance therapy to prevent NMO 
relapses. All studies that assessed current treatments 
to prevent NMO relapses were rated as Class IV evi-
dence, and most were observational and retrospective 
in nature. This includes all published rituximab, aza-
thioprine, steroid, mitoxantrone, and mycophenolate 
mofetil studies (list of references of these 49 studies is 
available upon request).
Typically, in the reviewed studies, the relapse rates in 
patients before and after a treatment is initiated were 
compared. Although many of these trials demon-
strated an improvement in annualized relapse rate 
(ARR) or Expanded Disability Status Scale (EDSS)14 
score, the analysis is confounded by the absence of a 
contemporaneous control group, the variability in 
dosing regimens, limited reporting of safety data, the 
use of historical measures to gauge ARR prior to 
treatment, and other factors. For example, patients are 
often studied shortly after experiencing an attack, 
which may have exaggerated the baseline ARR; the 
post-treatment ARR could appear lower due to the 
well-recognized phenomenon of “regression towards 
the mean.”15 These open-label observational studies 
rarely included sufficient methodological details to 
evaluate important confounding factors such as selec-
tion and information bias. Furthermore, the desire to 
identify a successful treatment may lead to biased 
reporting and evaluation of clinical data when the 
treatment assignment is not blinded. Based on this 
systematic review and applying the AAN treatment 
guidelines, all current treatments to prevent NMO 
relapses would be classified as “U” and therefore do 
not fulfill the criteria for establishing clinical guide-
lines or “standard of care” in the strict sense.
Although the European Federation of Neurological 
Societies (EFNS) guideline on management of NMO 
recommends immunosuppressive treatment, it also 
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recognizes that there is “currently only class IV evi-
dence for effect of any medication for relapse preven-
tion” and that their recommendations are “based on 
expert opinion.”16 Additional treatment guidelines 
published by expert consensus groups17,18 are also 
based on Class IV evidence. Whether one believes it 
is appropriate to have a placebo control in an NMO 
trial often depends on how strongly one believes that 
the currently used therapies have an unequivocally 
positive risk/benefit ratio. The available evidence is 
not strong enough to establish a standard of care that 
would prohibit a placebo-controlled trial in NMO.4,5 
Once a treatment is established as effective and safe 
via a placebo-controlled, randomized trial, that treat-
ment will become the standard of care, and a placebo 
control may not be needed or justified in subsequent 
NMO trials.
Ethical considerations for placebo-controlled 
studies in NMO
Similar to any other clinical investigation, placebo-
controlled NMO treatment trials must respect patient 
autonomy, sufficiently balance risks and benefits, 
provide inherent value, and maintain justice. Of spe-
cial interest in the NMO case are (1) the severity of 
the attacks, (2) the rarity of the condition, (3) the qual-
ity of evidence supporting use of current empirical 
treatments, and (4) disagreement within the clinical 
and scientific communities about the acceptability of 
a placebo arm in NMO clinical trials.
Clinical equipoise
Clinical equipoise requires (1) uncertainty (or honest 
professional disagreement in the community of 
experts) about the relative scientific and clinical mer-
its of each of the treatment arms of the trial and (2) 
consistency of each treatment arm with competent 
medical care. The first of these requirements exists 
for NMO therapy; that is, we are uncertain whether 
and by how much the new treatment is better than no 
treatment or better than what is currently used empiri-
cally. The second requirement hinges on whether pla-
cebo can be considered competent medical care. This, 
in turn, depends on clinicians’ judgment of the risks of 
harm and the adequacy of the evidence of the effect of 
current empiric treatments.
Some assert that placebo treatment may represent a 
breach of a physician’s “duty of care.” If clinical equi-
poise exists, then a duty of care is not being breached. 
The decision regarding which comparator is ethically 
appropriate depends on (1) a value judgment about 
the adequacy of the evidence of the effect of the 
currently used treatments, (2) a value judgment about 
the relative (scientific and clinical) value or impor-
tance of answering the “placebo” question versus the 
(scientific and clinical) value of answering the “what 
we currently do” question, and (3) a value judgment 
that compares this scientific and clinical value against 
the relative risk of harm to those in the placebo con-
trol group. These judgments are complex and require 
substantial clinical and researcher expertise and 
patient input. They also require openness and an inde-
pendent perspective.
Risk of harm
Given the potential severity of NMO relapses, risk 
of harm should be minimized for any clinical trial 
design, not only placebo-controlled trials. Several 
methodological strategies can be used to achieve this 
aim; however, none will remove the wrong of expos-
ing some participants to some harm. The need for 
ethical judgment is not removed by minimizing 
overall harm to participants even if harm can be mit-
igated. That being said, no study design can elimi-
nate all potential risks of harm. Harm may be caused 
by the disease under study or as an unintended 
consequence of treatment, for example, off-target 
effects. Part of the balance here rests on weighing 
the risks of harm associated with placebo (no treat-
ment) versus the risks of harm associated with treat-
ment. In the case of NMO, all current empiric 
therapies potentially cause harm including oppor-
tunistic infections and malignancies associated 
with immune suppressants. Potentially, the risks of 
current empiric treatments may be greater than 
placebo.
Consent
If the uncertainties associated with the available evi-
dence for using current therapies along with the 
potential scientific and clinical values are openly and 
adequately explained to potential participants, their 
informed consent can be obtained. Even if these dis-
cussions are difficult, complex, or differ from what 
has previously been discussed with the patient, 
informed consent is possible.
Rarity and severity
Finally, the rarity and the severity of NMO make a 
difference in the ethics of conducting research in this 
area. Since NMO is rare, we may think that the suffer-
ers should be more protected, or we may think we 
need to go to greater lengths to ensure that this 
research is conducted so that future suffering can be 
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avoided. In the case of severity, we are hesitant to 
expose patients with severe conditions to potential 
risk, yet the severity of the disease makes the impor-
tance of finding effective treatments even greater. 
These competing issues raise the stakes in NMO clin-
ical research and polarize the positions taken by 
stakeholders in this clinical research area. Therefore, 
even more we need to rely on the processes that we 
use to make these judgments, and this require open-
ness, independence, and inclusiveness.
Features of the N-MOmentum study that will 
reduce the potential risk of placebo
Given the issues discussed above, the following 
design features were incorporated to mitigate the 
potential risk associated with a placebo-controlled 
study (Table 1).
Time-to-attack primary outcome
Relapses are the most medically relevant biological 
event in NMO, and proof of efficacy can be based on 
delaying and/or reducing the occurrence of relapses. 
Given the potential severity of NMO attacks, expos-
ing placebo-treated patients to multiple attacks during 
the randomized portion of the study was deemed to be 
unacceptable. In clinical practice, many neurologists 
initiate or switch treatment following an NMO attack. 
Therefore, the primary endpoint of this study is time-
to-attack within the masked, randomized, placebo-
controlled part of the study. This ensures that patients 
in this study and especially those on placebo will not 
experience more than one attack while on study drug. 
This endpoint has been used effectively in several 
clinical trials such as clinically isolated syndromes 
suggestive of initial demyelinating events associated 
Table 1. Challenges faced in the design of the N-MOmentum trial and the solutions that were implemented.
Issue Solution
Potential risk associated with the use of placebo Limit placebo exposure to 6.5 months
Utilize a time-to-event primary outcome rather than 
annualized relapse rate and thus limit to ONE the number of 
adjudicated relapses per patient during the randomized period
Enrolling into the open-label period following one 
adjudicated attack
Support an unblinded Data Safety Monitoring Board to 
monitor subject safety
Perform an interim futility analysis so that the study can be 
stopped early if the intervention is ineffective
Ensure a robust informed consent process
Desire to minimize the total number of relapses 
needed and the total number of placebo subjects 
needed
Use an unequal randomization scheme (3:1) of active to 
placebo subjects
Disease heterogeneity and generalizability of 
the study results to both AQP4-IgG seropositive 
and seronegative patients
Enroll both seropositive and seronegative subjects and stratify 
randomization by AQP4-IgG serostatus to facilitate subgroup 
analysis
Potential for NMO misdiagnosis Use standard diagnostic criteria in the inclusion criteria
Since seronegative patients are at higher risk of misdiagnosis 
than seropositive patients, utilize a review committee to 
confirm the diagnosis in seronegative subjects
Lack of objective criteria defining an NMO 
attack
Use of 18 specific relapse criteria that were developed for this 
study
Unclear role of how to use MRI to diagnose 
relapses
Utilize relapse criteria that are primarily based on clinical 
findings but allow MRI confirmation in specific scenarios in 
which the clinical findings are equivocal or nonspecific
Need for a large number of study sites, leading 
to potential variability in relapse assessment
Utilize clear, objective criteria for relapses
Adjudicate relapses using a committee of disease experts
Differing opinions about study design among 
regulators and other NMO stakeholders
Seek meaningful engagement with disease experts, patient 
representatives, ethicists, and regulators to inform the trial 
design
NMO: neuromyelitis optica; MRI: magnetic resonance imaging.
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with multiple sclerosis (MS).19–22 Patients who expe-
rience an attack are eligible for open-label treatment 
with MEDI-551, following investigator-determined 
rescue therapy. In the open-label period, patients will 
receive MEDI-551 every 6 months until the study is 
terminated or, if successful, until regulatory approval.
Limited duration of potential placebo exposure
Another study design element that reduces the risk of 
placebo exposure is limiting the duration of the rand-
omized controlled period to 6.5 months. Randomized 
controlled trials in MS have used a 6-month duration 
for proof-of-concept Phase II studies. Several pla-
cebo-controlled clinical trials in MS have shown a 
significant impact of treatment on MS relapse fre-
quency over a 6-month time frame (natalizumab,23 
fingolimod,24 rituximab,25 and ocrelizumab26). Given 
that the goal of this study is to show an impact on time 
to first relapse and that the frequency of relapses in 
NMO is expected to be higher than in MS, limiting 
the study to 6.5 months of placebo exposure will prob-
ably be sufficient to detect a clinically important treat-
ment effect and will enhance subject recruitment. 
Subjects who experience an adjudicated relapse or 
who complete the 6.5-month randomized controlled 
period without an adjudicated relapse will be offered 
participation in the open-label period.
Unequal randomization
Our estimate of the effect size of MEDI-551 is based 
on nonrandomized studies of rituximab. It is to be 
expected that MEDI-551 will share the same class 
effects that have been seen with other B-cell depleting 
agents in patients with NMO. Feedback from investi-
gators and patients indicated that 3:1 randomization 
would be easier to accept for a placebo-controlled 
design as opposed to 2:1 or 1:1. One downside of 
unequal randomization is that it increases the total 
number of patients needed in the trial, but not as much 
as an active agent comparative trial. However, the 3:1 
ratio requires fewer placebo patients (53, compared to 
56 and 65 in 2:1 and 1:1 ratios, respectively), and 
fewer attacks are estimated under the alternative 
hypothesis in the placebo group (27, compared to 30 
and 34 in 2:1 and 1:1 ratios, respectively).
Unblinded Data Safety Monitoring Board and 
interim futility analysis
Safety and efficacy data from the trial will be reviewed 
periodically by an unblinded Data Safety Monitoring 
Board (DSMB). They will be able to advise the study 
sponsor if any safety concerns are identified during 
the conduct of the trial. The DSMB will also perform 
an unblinded futility analysis after 34 attacks (~50% 
of the total expected attacks in the two study groups 
combined) occur. This will enable an early determi-
nation of whether the study is futile, thus potentially 
reducing the number of subjects who are exposed to 
an ineffective treatment.
Other considerations in the design of the 
N-MOmentum trial
Definition of the study population
Misdiagnosis of NMO as MS or other diseases is a 
clinical challenge that needs to be addressed in the 
design of an NMO clinical trial. Fortunately, the anti-
AQP4 antibody (AQP4-IgG) is highly specific for 
NMO/NMO spectrum disorders (NMOSD) and thus 
is very useful as a diagnostic biomarker. Hence, the 
main concern for potential misdiagnosis is for the 
seronegative patients. To increase the homogeneity of 
the study population, some trials have excluded seron-
egative patients. The disadvantage of this strategy is 
that the trial will exclude a cohort of patients who 
meet established diagnostic criteria27 and fail to estab-
lish clinical efficacy in this disease cohort. Along with 
seropositive patients, the N-MOmentum trial will 
enroll seronegative subjects who meet diagnostic cri-
teria for NMO27 (20% of subjects enrolled). To ensure 
that seronegative patients meet diagnostic criteria 
for NMO, a three-member independent Eligibility 
Committee will review all relevant data and confirms 
the diagnosis. The sample size determination for this 
study assumed that the proportion of AQP4-IgG sero-
positive cases is 80%. This strategy is well aligned 
with the principles outlined in US Food and Drug 
Administration (FDA)28 guidance on enrichment for 
definite cases, but not excluding cases without a bio-
marker, when there is a reasonable expectation that 
both those with and without the diagnostic biomarker 
may respond similarly.
Subjects will need to have experienced at least one 
clinical attack in the last year or two clinical attacks in 
the last 2 years. The age range for the trial is broad 
(18 years and above), and subjects are permitted to 
enter with significant neurological disability as 
reflected by EDSS range up to 8.0. Treatment with 
mycophenolate mofetil, azathioprine, or daily pred-
nisone is allowed up to the point of randomization. 
Rituximab-treated subjects will also be allowed at 
entry; however, these subjects will need to have B-cell 
repletion to at least the lower limit of normal. These 
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entry criteria will allow the participation of many 
NMO subjects, and results of the study could be gen-
eralizable to the majority of the NMO population.
Definition and adjudication of NMO attacks
As the primary outcome, it is critical that attacks are 
rigorously defined and specific criteria are imple-
mented to identify specific NMO-related events as 
early as possible. Because there are no evidence-
based definitions of NMO attacks, a panel of NMO 
experts defined 18 NMO attack criteria: 11 for optic 
neuritis, 4 for myelitis, 2 for brainstem, and 1 for 
hemispheric involvement (Table 2). These criteria are 
primarily clinical but utilize magnetic resonance 
imaging (MRI) for confirmation in cases where the 
clinical findings are equivocal or nonspecific. The US 
FDA accepted these criteria.
Three general types of NMO attacks have been 
described: (1) myelitis, (2) optic neuritis, and (3) 
brainstem or cerebral attacks. Myelitis attacks are 
based on a change in the pyramidal, sensory, or bowel 
and bladder Functional System (FS) scores of the 
EDSS that would be affected by this type of attack. 
In patients with clinically significant ambulatory 
impairment, a change in the EDSS score can be used 
to define an attack. In milder cases of myelitis, confir-
mation requires identification of a new, enlarging or 
active (gadolinium-enhancing) MRI lesion in the spi-
nal cord. Optic neuritis attacks are based on visual 
acuity changes and presence of a new relative afferent 
pupillary defect (RAPD). In milder cases of optic 
neuritis, confirmation requires documentation of 
a new, enlarging or active (gadolinium-enhancing) 
MRI lesion in the anterior visual pathway. For exam-
ple, a subject with a 10-character drop in high-con-
trast visual acuity and a new RAPD during an optic 
neuritis event would not need MRI confirmation. In 
contrast, a patient with a 5-character drop and no new 
RAPD would need to also have a new MRI lesion in 
the corresponding optic nerve to meet relapse criteria. 
Another example of the need for MRI-supported 
relapse criteria is the most common brainstem attack 
in NMO: a lesion in the area postrema that manifests 
with nausea, vomiting, or hiccups. When persistent, 
these symptoms fulfill the clinical requirements for a 
NMO relapse; however, given the lack of specificity 
of these symptoms, identification of an area postrema 
lesion on MRI is required to confirm inflammatory 
injury. For attacks that involve the cerebral hemi-
spheres, changes in relevant FS subscores can be used 
to define the relapse in conjunction with identification 
of an appropriately located new or active MRI brain 
lesion.
Given the rarity of this disease, the number of partici-
pating sites will be high and the number of patients 
enrolled at each site few. To minimize variability 
amongst the sites in determining the occurrence of 
NMO attacks, a three-member masked Adjudication 
Committee will review all attack assessments within 
14 days of attack assessment visit initiation. The com-
mittee will review clinical data, and when clinical cri-
teria require MRI confirmation, MRI data. Only 
adjudicated attacks will count toward the primary 
endpoint and allow subjects to enter into the open-
label period. However, the adjudication process will 
not influence the site investigator’s decision regard-
ing relapse treatment.
Maintenance of blinding
Because the behavior of patients, investigators, and 
assessors might be biased by beliefs about treatment 
allocation, it is critical to maintain blinding to treat-
ment allocation. The 3:1 randomization could lead 
site staff to assume (sometimes incorrectly) that the 
patient is on the active drug and thereby downplay 
relapse risk. However, the concern about the placebo 
may cause relapse over-diagnosis. The double-
masked design of the study is aimed at mitigating this 
risk. To further reduce the risk of bias, the study 
includes defined clinical criteria to assess the NMO 
attacks, masked EDSS and visual acuity assessors, 
and a central attack adjudication committee.
Statistical considerations
There were several challenges to determining the 
expected frequency of relapses in NMO in order to cal-
culate the trial sample size. First, because large-scale 
natural history studies in NMO have not been done, it 
was necessary to use a meta-analytic approach to eval-
uate recent literature. Second, evolving NMO diagnos-
tic criteria can affect relapse rate estimates using 
different NMO patient populations. Therefore, our 
analysis included studies that used the published diag-
nostic criteria for NMO that were in use at that time.27
Meta-analysis of recent literature led to estimates of 
the hazard rate for the placebo group to be 1.5 and 1.0 
relapses per year for seropositive and seronegative, 
respectively, based on the pre-treatment relapse fre-
quency.29–33 The target treatment effect (reduction in 
risk of attack) with MEDI-551 was estimated to be 
60% based on another meta-analysis of open-label 
azathioprine30 and rituximab studies.29,31,32 Thus, with 
3:1 randomization, target hazard ratio of 0.4, hazard 
rates in the placebo-treated group quoted above, and 
Type I error (two-sided) of 5%, the number of events 
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868 http://msj.sagepub.com
Table 2. NMO attack criteria.
Example symptoms of an 
NMO/NMOSD attacka
Attack typeb Protocol-defined attack criteriac
Blurred vision; loss of vision; 
eye pain
ON 1.   Greater than 15-character drop in high-contrast 
Landolt C Broken Rings Chart from last visit as 
measured in a previously affected eye and no other 
ophthalmological explanation
 2.   At least 2-step dropd in CF to NLP from last visit as 
measured in a previously affected eye and no other 
ophthalmological explanation
 3.   At least 7 or more character drop in low-contrast 
Landolt C Broken Rings Chart from last visit as 
measured in either eye alone (monocular) AND a 
new RAPD in affected eye
 4.   At least 7 or more character drop in low-contrast 
Landolt C Broken Rings Chart from last visit as 
measured in either eye alone (monocular) AND loss 
of a previously documented RAPD in fellow eye
 5.   At least 5 or more character drop in high-contrast 
Landolt C Broken Rings Chart from last visit as 
measured in either eye alone (monocular) AND a 
new RAPD in affected eye
 6.   At least 5 or more character drop in high-contrast 
Landolt C Broken Rings Chart from last visit as 
measured in either eye alone (monocular) AND loss 
of a previously documented RAPD in fellow eye
 7.   At least 1-step drope in CF to NLP from last visit as 
measured in a previously affected eye AND a new 
RAPD in affected eye
 8.   At least 1-step drope in CF to NLP from last visit as 
measured in a previously affected eye AND loss of a 
previously documented RAPD in fellow eye
 9.   At least 7 or more character drop in low-contrast 
Landolt C Broken Rings Chart from last visit as 
measured in either eye alone (monocular) AND a 
new Gd-enhancing or new/enlarging T2 MRI lesion 
in the corresponding optic nerve
 10. At least 5 or more character drop in high-contrast 
Landolt C Broken Rings Chart from last visit as 
measured in either eye alone (monocular) AND a 
new Gd-enhancing or new/enlarging T2 MRI lesion 
in the corresponding optic nerve
 11. At least 1-step drope in CF to NLP from last visit as 
measured in a previously affected eye AND a new 
Gd-enhancing or new/enlarging T2 MRI lesion in 
the corresponding optic nerve
Deep or radicular pain; 
extremity paresthesia; 
weakness; sphincter 
dysfunction; Lhermitte’s sign 
(not in isolation) 
 
Myelitisf 12. At least 2-point worsening in 1 or more of the 
relevant (pyramidal, bladder/bowel, sensory) FSS 
compared to last visit
13. At least 1-point worsening in EDSS score compared 
to last visit if previous EDSS score is 5.5 or more
14. At least 1-point worsening in 2 or more of the 
relevant (pyramidal, bladder/bowel, sensory) FSS 
compared to last visit when the last visit score was 
1 or greater AND a new Gd-enhancing or new/
enlarging T2 MRI lesion in the spinal cord
(Continued)
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needed is estimated as 67 to achieve 90% power to 
show a statistically significant difference between 
active treatment and placebo. Assuming 28 weeks of 
controlled randomized period, we predicted that the 
required sample will be approximately 212 subjects. 
If the actual on-study annual relapse hazard rate is 
less than expected, a larger number of subjects will be 
needed for the 67 relapses to occur within the 28-week 
randomized, controlled period. Randomization will 
be stratified by seropositivity to AQP4-IgG and by 
whether or not the patient is Japanese (to enable anal-
ysis of this subpopulation). Figure 1 outlines the study 
design schematically.
Regulatory and community perspective
Key to the success of any clinical development pro-
gram is regulatory acceptance. Like the medical com-
munity as a whole, regulatory agencies have provided 
a spectrum of opinions on the optimal trial design 
with regard to use of a placebo control. Following 
public discussion as well as direct exchange of opin-
ion between the study sponsor and the regulatory 
agencies, most regulatory authorities around the 
world have accepted the N-MOmentum study design.
As of 31 August 2015, 118 sites have been identified 
and agreed to participate. Numerous letters of support 
were received from principal investigators and key 
opinion leaders in NMO from around the world. In 
all, 21 countries’ regulatory authorities and country-
level ethics committees/institutional review boards 
(IRBs) have approved the study. More importantly, as 
of the time of writing, 57 patients from different parts 
of the world have signed an informed consent and 
entered the study; of these, 21 have been randomized 
into the two treatment arms of the study.
Conclusion
NMO poses a number of development challenges 
because it is a rare, severe disease with no proven 
Example symptoms of an 
NMO/NMOSD attacka
Attack typeb Protocol-defined attack criteriac
 15. At least 0.5-point worsening in EDSS score 
compared to last visit if previous EDSS score is 5.5 
or more AND a new Gd-enhancing or new/enlarging 
T2 MRI lesion in the spinal cord
Nausea; intractable vomiting; 
intractable hiccups; other 
neurological signs (e.g. double 
vision, dysarthria, dysphagia, 
vertigo, oculomotor palsy, 
weakness, nystgmus, other 
cranial nerve abnormality) 
Brainstem 16. Isolated (not present at last visit) intractable nausea, 
vomiting, and/or hiccups lasting for greater than 
48 hours AND a new Gd-enhancing or new/enlarging 
T2 MRI lesion in the brainstem
17. At least 2-point worsening in 1 or more of the 
relevant (brainstem, cerebellar) FSS compared to last 
visit AND a new Gd-enhancing or new/enlarging T2 
MRI lesion in the brainstem
Encephalopathy; hypothalamic 
dysfunction
Brain 18. At least 2-point worsening in 1 or more of the 
relevant (cerebral, sensory, pyramidal) FSS (with 
a score of 3 or more at the current visit) compared 
to last visit AND a new Gd-enhancing or new/
enlarging T2 MRI lesion in the brain consistent with 
the clinical presentation
CF: counting fingers; EDSS: Expanded Disability Severity Score; FSS: Functional System Scores; Gd: gadolinium; HM: hand mo-
tion; LP: light perception; MRI: magnetic resonance imaging; NLP: no light perception; NMO/NMOSD: neuromyelitis optica/neuro-
myelitis optica spectrum disorders; ON: optic neuritis; RAPD: relative afferent pupillary defect.
aThe symptoms listed are examples and are not inclusive of all NMO/NMOSD symptoms.
b Four major areas of the body may be affected by an attack: the optic nerve, resulting in ON; the spinal cord, resulting in myelitis; 
the brainstem, resulting in a number of outcomes; and the brain.
c Symptom(s) must meet at least one of the objective criteria for an NMO/NMOSD attack. However, the symptom(s) may meet more 
than one of the criteria for an NMO/NMOSD attack across different body systems.
d At least 2-step drop can be any of the following worsening: on Landolt C Broken Rings Chart to HM, LP, or NLP; CF to LP or 
NLP; and HM to NLP.
e At least 1-step drop can be any of the following worsening: on Landolt C Broken Rings Chart to CF, HM, LP, or NLP; CF to HM or 
LP or NLP; and LP to NLP.
f A 1-point change in a single FSS without a change in the EDSS, with or without a new Gd-enhancing or new/enlarging T2 MRI le-
sion in the spinal cord, is not considered a clinically significant change and will not count as an attack per this protocol.
Table 2. (Continued)
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therapies and is currently treated empirically. Since 
registration studies have not been conducted in 
NMO, agreed endpoints and study designs are addi-
tional challenges. In this setting of a rare disease with 
unequivocal unmet need, conducting the most robust 
trial to provide interpretable data is critical. We 
described the status of current treatments and the 
ethical considerations that led to the N-MOmentum 
clinical trial that is specifically designed to mitigate 
the risks of placebo control while maintaining scien-
tific rigor.
The medical/scientific community, patient organiza-
tions, and regulatory authorities were engaged in 
early discussions on this study, and their input con-
tributed to the final study design. As a result, the 
N-MOmentum study design has garnered global regu-
latory, ethical, clinical, and patient approval. Similar 
considerations should be addressed in advance for 
any rare disease with no approved medications.
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